Validation of the Urticaria Activity Score for Cold Urticaria

IF 6.6 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice Pub Date : 2025-09-01 DOI:10.1016/j.jaip.2025.04.012

Eva Grekowitz MD , Pascale Salameh PhD , Sabine Altrichter MD , Dalia M. Ahsan MD , Karsten Weller MD , Martin Metz MD , Manuel P. Pereira MD, PhD , Dorothea Terhorst-Molawi MD

{"title":"Validation of the Urticaria Activity Score for Cold Urticaria","authors":"Eva Grekowitz MD , Pascale Salameh PhD , Sabine Altrichter MD , Dalia M. Ahsan MD , Karsten Weller MD , Martin Metz MD , Manuel P. Pereira MD, PhD , Dorothea Terhorst-Molawi MD","doi":"10.1016/j.jaip.2025.04.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cold urticaria (ColdU) is characterized by the appearance of wheals and/or angioedema and itch after exposure to cold stimuli. The Cold Urticaria Activity score (ColdUAS) is a newly devised patient-reported outcome measure (PROM) assessing disease activity in ColdU.</div></div><div><h3>Objectives</h3><div>We aimed to validate the ColdUAS according to PROM guidelines, assess the optimal documentation period, and develop a scoring computation algorithm.</div></div><div><h3>Methods</h3><div>We instructed 71 patients with typical and atypical ColdU to complete the ColdUAS questionnaire over 4 consecutive weeks and asked to fill out additional anchor instruments including global assessment tools and validated quality of life measures. The scoring computation for the ColdUAS was developed by an expert group and the questionnaire was tested for its construct, structural, convergent, and known-groups validity as well as for its reliability including internal consistency and test-retest reliability.</div></div><div><h3>Results</h3><div>The ColdUAS is calculated from the first three questions in the ColdUAS questionnaire, and the optimal assessment period was 2 weeks. We developed a calculation sheet to facilitate its use. The score demonstrates robust construct, structural, and convergent validity, as well as validity among known groups. It exhibits high reliability, including internal consistency and test-retest reliability.</div></div><div><h3>Conclusions</h3><div>The ColdUAS is a newly developed PROM to assess disease activity in adolescent and adult patients with typical or atypical ColdU, tailored to the specific symptoms of these patients. The validation study confirmed its validity and reliability as a valuable tool in routine care and clinical research.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2329-2337.e3"},"PeriodicalIF":6.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221321982500368X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cold urticaria (ColdU) is characterized by the appearance of wheals and/or angioedema and itch after exposure to cold stimuli. The Cold Urticaria Activity score (ColdUAS) is a newly devised patient-reported outcome measure (PROM) assessing disease activity in ColdU.

Objectives

We aimed to validate the ColdUAS according to PROM guidelines, assess the optimal documentation period, and develop a scoring computation algorithm.

Methods

We instructed 71 patients with typical and atypical ColdU to complete the ColdUAS questionnaire over 4 consecutive weeks and asked to fill out additional anchor instruments including global assessment tools and validated quality of life measures. The scoring computation for the ColdUAS was developed by an expert group and the questionnaire was tested for its construct, structural, convergent, and known-groups validity as well as for its reliability including internal consistency and test-retest reliability.

Results

The ColdUAS is calculated from the first three questions in the ColdUAS questionnaire, and the optimal assessment period was 2 weeks. We developed a calculation sheet to facilitate its use. The score demonstrates robust construct, structural, and convergent validity, as well as validity among known groups. It exhibits high reliability, including internal consistency and test-retest reliability.

Conclusions

The ColdUAS is a newly developed PROM to assess disease activity in adolescent and adult patients with typical or atypical ColdU, tailored to the specific symptoms of these patients. The validation study confirmed its validity and reliability as a valuable tool in routine care and clinical research.

查看原文本刊更多论文

寒性荨麻疹（ColdUAS）的荨麻疹活动评分的验证。

背景：冷性荨麻疹（ColdU）的特征是暴露于冷刺激后出现皮疹和/或血管性水肿和瘙痒。ColdUAS（寒性荨麻疹活动度评分）是一种新设计的评估寒性荨麻疹疾病活动度的患者报告结果测量（PROM）。目的：根据PROM指南对ColdUAS进行验证，评估最佳记录周期，并开发评分计算算法。方法：71例典型和非典型ColdU患者在连续四周的时间内完成ColdUAS问卷，并要求填写其他锚定工具，包括整体评估工具和经过验证的生活质量测量。ColdUAS的计分计算由专家组制定，并对问卷的结构效度、结构效度、收敛效度和已知组效度以及内部一致性和重测信度进行了检验。结果：ColdUAS评分由ColdUAS问卷前三个问题计算，最佳评估期为2周。为方便使用，编制了计算表。该分数表现出稳健的结构效度、结构效度和收敛效度，以及已知组间的效度。它具有较高的信度，包括内部一致性和重测信度。结论：ColdUAS是一种新开发的PROM，用于评估青少年和成人典型或非典型ColdU患者的疾病活动性，针对这些患者的特定症状量身定制。验证性研究证实了其在常规护理和临床研究中的有效性和可靠性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Allergy and Clinical Immunology-In Practice ALLERGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

11.10

自引率

9.60%

发文量

683

审稿时长

50 days

期刊介绍： JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases. This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.